🇺🇸 FDA

Company profile · Sponsor

Actinium

Actinium Pharmaceuticals

ATNM · NYSE pharma NEW YORK, NY, USA
Pipeline
8
Drugs
0
Patents
8

Quick answer

Actinium (ATNM) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ATNM
Exchange NYSE
Company type pharma
Headquarters NEW YORK, NY, USA
SEC CIK 0001388320

Pipeline (8)

Search pipeline →

  1. 131I-apamistamab

    Actinium

    Acute Leukemia

    phase 3 small molecule active

    1 trial

  2. Iomab-B

    Actinium

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  3. Cytarabine (Phase 1 only)

    Actinium

    AML

    phase 2 small molecule completed

    1 trial

  4. Iomab-B

    Actinium

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  5. Lintuzumab-Ac225

    Actinium

    Acute Myeloid Leukemia

    phase 2 mab active

    2 trials

  6. 131I-apamistmab

    Actinium

    Sickling Disorder Due to Hemoglobin S

    phase 1 small molecule active

    1 trial

  7. ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195

    Actinium

    Leukemia

    phase 1 mab completed

    1 trial

  8. Lintuzumab AC 225

    Actinium

    Refractory Multiple Myeloma

    phase 1 small molecule terminated

    1 trial

Patents (8)

Search patents →

  1. US 12410249

    Low dose antibody-based methods for treating hematologic malignancies

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12133849

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12083192

    Methods for treatment of patients with myelodysplastic syndromes

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11981741

    Humanized anti-CD45 antibodies

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11975081

    Bifunctional chelators and conjugates

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11964948

    Bifunctional chelators and conjugates

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11912780

    Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11844799

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Actinium?

Actinium (ATNM) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Actinium sponsor?

We track 8 ClinicalTrials.gov-linked programs for Actinium, including 131I-apamistamab and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Actinium company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.